Research Division, Chugai Pharmaceutical Co., Ltd., 1-135, Komakado, Gotemba, Shizuoka, 412-8513, Japan.
Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-0856, Japan.
Sci Rep. 2021 Apr 16;11(1):8383. doi: 10.1038/s41598-021-87912-6.
Evaluation of the binding and uptake of an antibody in liver non-parenchymal cells (NPC), including liver sinusoidal endothelial cells, is important for revealing its pharmacokinetic (PK) behavior, since NPC has important roles in eliminating an antibody from the blood via the Fc fragment of IgG receptor IIB (FcγRIIB). However, there is currently no in vitro quantitative assay using NPC. This study reports on the development of a cell-based assay for evaluating the binding and uptake of such an antibody using liver NPC of mice and monkeys. In mice, the FcγRIIB-expressing cells were identified in the CD146-positive and CD45-negative fraction by flow cytometry. A titration assay was performed to determine the PK parameters, and the obtained parameter was comparable to that determined by the fitting of the in vivo PK. This approach was also extended to NPC from monkeys. The concentration-dependent binding and uptake was measured to determine the PK parameters using monkey NPC, the FcγRIIB-expressing fraction of which was identified by CD31 and CD45. The findings presented herein demonstrate that the in vitro liver NPC assay using flow cytometry is a useful tool to determine the binding and uptake of biologics and to predict the PK.
评估抗体在肝非实质细胞(NPC)中的结合和摄取非常重要,因为 NPC 可通过 IgG 受体 IIB(FcγRIIB)的 Fc 片段将抗体从血液中清除,从而影响其药代动力学(PK)行为。然而,目前还没有使用 NPC 的体外定量检测方法。本研究报告了一种基于细胞的方法,用于使用小鼠和猴的肝 NPC 评估此类抗体的结合和摄取。在小鼠中,通过流式细胞术鉴定出 CD146 阳性、CD45 阴性的 FcγRIIB 表达细胞。进行了滴定测定以确定 PK 参数,所得参数与体内 PK 拟合确定的参数具有可比性。该方法还扩展到来自猴子的 NPC。通过测量浓度依赖性结合和摄取,使用猴子 NPC 确定 PK 参数,其 FcγRIIB 表达部分通过 CD31 和 CD45 进行鉴定。本文的研究结果表明,使用流式细胞术的体外肝 NPC 测定是一种有用的工具,可用于确定生物制剂的结合和摄取,并预测 PK。